8-K: Envista Holdings Reports Strong Q1 2026 Results

Envista Holdings Corporation announced robust first quarter 2026 results, with 9.5% core revenue growth, significant increases in adjusted EBITDA and EPS, and a new $300 million share repurchase program.

Summary

• Envista Holdings Corporation reported strong first quarter 2026 financial results, with sales reaching $706 million, a 9.5% increase in core revenue compared to the prior year.
• Adjusted EBITDA grew by 25% year-on-year to $99 million, with an improved adjusted EBITDA margin of 14.0%.
• Adjusted diluted Earnings Per Share (EPS) saw a substantial 50% increase year-on-year, reaching $0.36.
• Both major business segments, Specialty Products & Technologies and Equipment & Consumables, delivered positive core growth.
• The company reaffirmed its full-year 2026 guidance and announced an additional $300 million share repurchase program.
• Operating cash flow was negative $3 million and free cash flow was negative $16 million for the quarter.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, significant improvements in profitability metrics (EBITDA and EPS), and a commitment to returning capital to shareholders through an expanded share repurchase program, while reaffirming full-year guidance.

Positives

• Core revenue growth of 9.5% driven by customer engagement and new product commercialization.
• Adjusted EBITDA increased by 25% to $99 million, with a margin expansion of 120 basis points to 14.0%.
• Adjusted diluted EPS grew by 50% to $0.36.
• Positive core growth in both Specialty Products & Technologies (8.4%) and Equipment & Consumables (11.5%) segments.
• Gross Margin improved by 100 basis points and adjusted EBITDA margin by 120 basis points, attributed to the Envista Business System (EBS).
• Reaffirmation of full-year 2026 guidance.
• Announcement of an incremental $300 million share repurchase program.

Negatives

• Operating cash flow was negative $3 million for the quarter, a decrease from $0 million in the prior year.
• Free cash flow was negative $16 million, a decrease from negative $5 million in the prior year.
• Cash and cash equivalents decreased from $1,211.7 million at December 31, 2025, to $1,082.8 million at April 3, 2026.

Risks

• The filing lists numerous factors that could cause actual results to differ materially from forward-looking statements, including global economic conditions, inflation, interest rates, slower economic growth or recession, international economic and political factors, debt obligations, trade policies, market contractions, commodity costs, supply chain disruptions, disasters, public health issues, security breaches, AI system usage, inventory fluctuations, distributor performance, competition, new product development, key personnel retention, improper conduct, regulatory compliance, clinical trial results, product modifications, health care industry changes, acquisition integration, intellectual property protection, restructuring activities, goodwill impairment, accounting standards, currency exchange rates, tax laws, litigation, product defects, and labor matters.

Future Outlook

The company is maintaining its full-year 2026 guidance, projecting core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, adjusted diluted EPS between $1.35 and $1.45, and free cash flow conversion of approximately 100%.

Management Comments

• "We delivered a good start to 2026, with first quarter results reflecting continued strong execution and progress in support of our strategic priorities."
• "We delivered growth across all our major businesses, driven by customer engagement and new product commercialization."
• "Our 9.5% core revenue growth converted to 25% adjusted EBITDA and 50% EPS growth, while also supporting double-digit increases in R&D and Sales & Marketing investment."
• "With momentum continuing, we are reaffirming our full-year guidance and announcing an incremental $300 million share repurchase program."

Industry Context

StockSavvy.ai notes that Envista's performance in the dental industry, characterized by growth in both specialty products and consumables, aligns with a sector focused on innovation and patient care. The company's emphasis on R&D and sales & marketing investment, alongside its strategic use of the Envista Business System, suggests a proactive approach to market dynamics and competitive pressures.

Comparison to Industry Standards

• Envista's reported core revenue growth of 9.5% for Q1 2026 is a strong indicator in the competitive dental market. While specific direct competitors' Q1 2026 results are not detailed in this filing, this growth rate generally outperforms broader economic indicators and suggests effective market penetration.
• The 120 basis point expansion in adjusted EBITDA margin to 14.0% indicates operational efficiency gains, which is a key benchmark for profitability in the medical device and consumables sector.
• The 50% year-on-year increase in adjusted diluted EPS is a significant positive, demonstrating strong leverage of revenue growth to bottom-line profitability, a metric closely watched by investors across the healthcare industry.

Stakeholder Impact

• Shareholders: Benefit from the announced incremental $300 million share repurchase program, potentially increasing earnings per share and share value.
• Employees: Continued gains in employee engagement and talent development are noted, suggesting a positive internal environment.
• Customers: Growth driven by customer engagement and new product commercialization indicates continued focus on meeting customer needs.
• Suppliers: While not explicitly mentioned, operational efficiency gains and growth may imply stable or increasing demand for supplies.

Next Steps

• Investor conference call on May 6, 2026, to discuss quarterly results and 2026 outlook.
• Webcast of the conference call and presentation available on the company's investor website.
• Replay of the webcast and conference call available on the company's investor website.

Key Dates

Recommendation

The company delivered strong Q1 results with significant growth in key profitability metrics and reaffirmed full-year guidance, alongside a substantial share repurchase program. However, the negative free cash flow and ongoing macro uncertainties mentioned in the risk factors warrant a cautious 'hold' recommendation until further sustained performance and cash flow generation are demonstrated.

Keywords

Envista Holdings, NVST, Q1 2026 Results, Dental Industry, Financial Report, Earnings, EBITDA, Share Repurchase